All In Biotech

Drug Trial Radar · NCT07502222

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Apr 7, 2026

Primary completion

Nov 2027

Study completion Jan 10, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.

Conditions

  • Moderate-to-Severe Atopic Dermatitis

Interventions

  • AK139 and placeboBiological

    AK139 plus placebo regimen 1-subcutaneous injection.

  • AK139Biological

    AK139 regimen 2-subcutaneous injection.

  • AK139 and placeboBiological

    AK139 plus placebo regimen 3-subcutaneous injection.

  • AK139Biological

    AK139 regimen 4-subcutaneous injection.

  • AK139 and placeboBiological

    AK139 plus placebo regimen 5-subcutaneous injection.

  • AK139 and placeboBiological

    AK139 plus placebo regimen 6-subcutaneous injection.

  • PlaceboBiological

    Placebo-subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity grading of Adverse Events (AE)(applicable to Part 1)Time frame: Up to Week 16 (applicable to the Q4W dosing group); Up to Week 8 (applicable to the Q2W dosing group).
  2. Percentage of patients who achieved Eczema Area and Severity Index (EASI)-75 (applicable to Part 2)Time frame: at week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.